# BIOA — BioAge Labs Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** BIOA  
**Sources:** 19  
**Published:** 2026-10-25  
**Canonical:** https://app.k3vl4r.com/research/deep-research-bioa-bioage-labs-inc-catalysts-narrative-risks-9127

---

## BioAge Labs (BIOA) — Point-in-Time Snapshot

BioAge Labs, Inc. trades on the NASDAQ under ticker BIOA and is a clinical-stage biopharmaceutical company developing therapeutic candidates for cardiometabolic diseases by targeting the biology of human aging. Its lead candidate, BGE-102, is an oral, brain-penetrant small-molecule NLRP3 inhibitor [[2]](https://markets.businessinsider.com/news/stocks/bioage-labs-to-present-at-upcoming-investor-conferences-1036575592)[[7]](https://www.advfn.com/stock-market/NASDAQ/BIOA/stock-news/99059454/bioage-labs-reports-second-quarter-2026-financial)[[8]](https://finance.yahoo.com/healthcare/articles/bioage-labs-reports-second-quarter-205000382.html)[[14]](https://stockanalysis.com/stocks/bioa/).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-bioa-bioage-labs-inc-catalysts-narrative-risks-9127 (free to sign up)._
